| 24/01 | Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for A.. |  |
| 23/01 | Blueprint Medicines Gets FDA's Priority Review For Ayvakit Supplemental New Drug Applic.. | |
| 23/01 | Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocyto.. | |
| 23/01 | Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for A.. | |
| 23/01 | Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Appli.. | |
| 17/01 | Taiwan Approves CStone Pharmaceuticals' New Drug Application for Lung, Thyroid Cancer T.. | |
| 09/01 | Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo.. | |
| 06/01 | Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements.. | |
| 06/01 | Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors | |
| 06/01 | Blueprint Medicines Corporation Announces Board Changes | |
| 05/01 | Blueprint Medicines Expects to Hit High End of 2022 Revenue Target Range | |
| 04/01 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 04/01 | North American Morning Briefing: Futures Rise -2- | |
| 2022 | Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements.. | |
| 2022 | Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Develo.. | |
| 2022 | Insider Sell: Blueprint Medicines | |
| 2022 | Blueprint Medicines Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year.. | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Blueprint Medicines Submits Supplemental New Drug Application for Ayvakit to US FDA for.. | |
| 2022 | Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avap.. | |
| 2022 | Blueprint Medicines to Present at Upcoming Investor Conferences | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a.. | |
| 2022 | Blueprint Medicines Posts Wider Q3 Loss, Revenue Rises | |
| 2022 | Blueprint Medicines : Q3 Earnings Snapshot | |
| 2022 | Blueprint Medicines Corp : Results of Operations and Financial Condition, Regulation FD Di.. | |
| 2022 | Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q3 Revenue $66M | |
| 2022 | Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q3 Loss $-2.23 | |
| 2022 | Blueprint Medicines Corporation Reports Earnings Results for the Third Quarter and Nine.. | |
| 2022 | Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and .. | |
| 2022 | Blueprint Medicines Corporation Provides Revenue Guidance for 2022 | |
| 2022 | Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Resu.. | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Blueprint Medicines : Management Change/Compensation - Form 8-K | |
| 2022 | Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo.. | |
| 2022 | Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo.. | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| 2022 | Blueprint Medicines Demonstrates Systemic Mastocytosis' Symptoms; Shares Rise | |
| 2022 | CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Syste.. | |
| 2022 | Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substant.. | |
| 2022 | Insider Sell: Blueprint Medicines | |
| 2022 | Insider Sell: Blueprint Medicines | |
| 2022 | Blueprint Medicines' Positive Topline Results in Ayvakit Trial Could Support Potential .. | |
| 2022 | Blueprint Medicines Reports Positive Top-line Results in Non-Advanced Systemic Mastocyt.. | |
| 2022 | Sector Update: Health Care Stocks Slip Premarket Wednesday | |
| 2022 | Blueprint Medicines Corp : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 2022 | Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® .. | |
| 2022 | Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® .. | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 2022 | BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a.. | |
| 2022 | Blueprint Medicines Reports Wider Q2 Loss as Revenue Advances, Full-Year Sales Guidance.. | |
| 2022 | Blueprint Medicines : Reports Second Quarter 2022 Results - Form 8-K | |
| 2022 | Blueprint Medicines : Q2 Earnings Snapshot | |
| 2022 | Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q2 Loss $-2.68 | |
| 2022 | Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q2 Revenue $36.5M | |
| 2022 | Blueprint Medicines Reports Second Quarter 2022 Results | |
| 2022 | Blueprint Medicines Corporation Reports Earnings Results for the Second Quarter and Six.. | |
| 2022 | Blueprint Medicines Corporation Provides Revenue Guidance for 2022 | |
| 2022 | Blueprint Medicines Corporation announced that it has received $400 million in funding | |
| 2022 | Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August .. | |
| 2022 | Blueprint Medicines Publishes Inaugural Corporate Responsibility Report | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 2022 | Blueprint Medicines Corp : Entry into a Material Definitive Agreement, Creation of a Direc.. | |
| 2022 | Blueprint Medicines Secures $1.25 Billion Strategic Financing Via Partnerships with Roy.. | |
| 2022 | Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to .. | |
| 2022 | Blueprint Medicines Corporation announced that it expects to receive $400 million in fu.. | |
| 2022 | Blueprint Medicines Corp : Change in Directors or Principal Officers, Submission of Matter.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines Corporation(NasdaqGS:BPMC) drop.. | |
| 2022 | Blueprint Medicines : Appoints Habib Dable to its Board of Directors - Form 8-K | |
| 2022 | Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements.. | |
| 2022 | Blueprint Medicines Appoints Habib Dable to its Board of Directors | |
| 2022 | Blueprint Medicines Appoints Habib Dable to its Board of Directors | |
| 2022 | Blueprint Medicines Shares Decline After Citigroup Downgrade | |
| 2022 | Blueprint Medicines Corp : Regulation FD Disclosure, Other Events, Financial Statements an.. | |
| 2022 | Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of.. | |
| 2022 | Blueprint Medicines Corporation Announces Updates on AYVAKIT/AYVAKYT | |
| 2022 | Insider Sell: Blueprint Medicines | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 2022 | Insider Sell: Blueprint Medicines | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 2022 | BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a.. | |
| 2022 | Blueprint Medicines : Q1 Earnings Snapshot | |
| 2022 | Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q1 Revenue $62.7M, vs. St.. | |
| 2022 | Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended Ma.. | |
| 2022 | Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022 | |
| 2022 | Blueprint Medicines Corp : Regulation FD Disclosure (form 8-K) | |
| 2022 | Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2.. | |
| 2022 | SK Inc. - Biopharm Investment and Sister Company Sign Collaborations to Advance Promisi.. | |
| 2022 | Blueprint Medicines Reports BLU-945 Trial Data | |
| 2022 | Blueprint Medicines Corp : Regulation FD Disclosure, Other Events, Financial Statements an.. | |
| 2022 | Blueprint Medicines Corporation Announces Blu-945 Proof-Of-Concept Data Supporting Init.. | |
| 2022 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 2022 | Blueprint Medicines Says European Commission Expands Indication for Ayvakyt to Advanced.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
